nanoform
small is powerful®

Nanoform Management Presentation

Q2 2024 Interim Report

August 29th, 2024

Disclaimer

Forward-Looking Statements

This presentation contains forward-looking statements, including, without limitation, statements regarding Nanoform's strategy, business plans and focus. The words may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," believe," "estimate," "predict," "project," "potential," "continue," "target" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this presentation are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this presentation, including, without limitation, any related to Nanoform's business, operations, clinical trials, supply chain, strategy, goals and anticipated timelines, competition from other companies, and other risks described in the Report of the Board of Directors and Financial Statements for the year ended December 31, 2023 as well as our other past disclosures. Nanoform cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. Nanoform disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. Any forward-looking statements contained in this presentation represent Nanoform's views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date.

Introduction

CEO Edward Hæggström

The structural pharma R&D problem in the pharma industry

Fewer than 50 drugs approved in the US annually on average…

Annual number of novel drug approvals by FDA 2010-2023



…while the global pharma industry R&D expenditure exceeds $200B

Global pharmaceutical R&D spending 2014-2028E (USDbn)



➢ **A game changer is needed to improve R&D yield**

Source: U.S. Food and Drug Administration (FDA); IQVIA Institute for Human Data Science; Statista; Nature

Low bioavailability is the key issue

Poor bioavailability and low efficacy most common reasons for drug failure

Reasons for drug failure in pre-clinical trials (share of molecules)



Majority of new drugs suffer from poor solubility



➢ **Nanoform can enhance the pharma industry output by targeting poorly soluble drugs**

Source: GlobalData 2009, Cutting Edge Water-based Nanotechnology in Drug Development (Reasons for drug failure); Nikolakakis & Partheniadis (2017), Self-Emulsifying Granules and Pellets: Composition and Formation Mechanisms for Instant or Controlled Release (Share of poorly soluble drugs) 1) Classification of drug substance according to Biopharmaceutics Classification System (BCS)

Particle size is key

Smaller particle size can improve a drug's bioavailability



- The surface area increases 30 fold from a 10 micron[1] sized particle once the particle size is reduced to 100nm
- Reduction of particle size down to 50nm increases the surface area by 1,000 fold



- Smaller particles have a larger surface area
- Larger surface area of particles enables improved bioavailability of a drug
- Improved bioavailability implies increased absorption of a drug by the body's circular system
- CESS® can produce API with large surface areas which can significantly improve the bioavailability of drugs

➢ CESS® produced nanoparticles have a larger surface area and as such improved bioavailability.

Proprietary technology platforms

Small molecules	***Large molecules***	***Nanoformulation***	***AI***
CESS®* technology enables new medicines through improved bioavailability of the API*	**Our unique biologic nanoparticles enable improved administration routes, by higher drug load and extended long-acting delivery**	**Full therapeutic potential is unlocked with nano-formulated API's, by highly differentiated novel nanoformulations**	**STARMAP® online is the digital twin of our CESS® process. It picks winners by detailed expert knowledge and sparse data AI**

Small molecules - Small is powerful®



Nanoform is here to fill the gap

Enabling new drugs

> 20,000 drugs in development*

Improving existing drugs

> 5,800 existing drugs*

Giving unsuccessful drug candidates a second chance

> 58,000 failed drugs in the last 40 years*

Source: Nanoform and Pharmaprojects® | Informa, 2022

Nanoform business highlights YTD

- ✓ Broad interest with potential commercialization partners on nanoenzalutamide and development partners on our other product kernels – first deals to be signed in 2024
- ✓ Increased biologics traction after Takeda presenting Nanoform's high concentration formulation technology at DDF in Berlin in May 2024
- ✓ 13 new customer projects signed so far in 2024, including 3 multi-API projects with major pharma
- ✓ FIMEA* approved our GMP* Quality Control lab
- ✓ GMP manufacturing ongoing in two shift pattern – 2024 manufacturing volume >10x vs 2023

- On track to meet 2024 business targets
- Targeting nanoenzalutamide to be the first Nanoformed medicine to reach the market (2027/2028 in EU/USA)
- Coming five years - preparing & launching Nanoformed products with partners onto global markets

*FIMEA = Finnish Medicines Agency
*GMP = Good Manufacturing Practice

Financials

CFO Albert Hæggström

Nr of employees & nr of lines





Nr of proposals sent and non-GMP projects signed





Nr of projects generating revenue





Quarterly and rolling 12 months revenue





***Impact on revenue can in a quarter(s) for some of the projects be negative if budgeted costs increase significantly (often related to hours worked).**

Project Nanoenzalutamide has increased external GMP QC cost





Excluding the cost of external GMP QC services, related to the nanoenzalutamide project, our underlying gross margin has remained above 90%. After receiving the Quality Control license from FIMEA in August we have started to insource the GMP QC work. This should start to have a positive effect on the gross margin from 4Q24 forward.

Improvement in operating free cash flow continues





At the end of 2Q24, Nanoform had more than EUR 50m in cash & short-term government bonds and no debt.

Nanoform near-term business targets 2024

Topic	Target	Status
Customer Projects	*Increased number of non-GMP and GMP projects signed in 2024 vs 2023 **	*On track*
Operating Free Cashflow	*Improved operating free cashflow in 2024 vs 2023 ***	*On track*
Commercialization	*To sign one or several license/commercial supply agreements during 2024*	*On track*

GMP = Good Manufacturing Practice
** 22 non-GMP and 1 GMP projects signed in 2023*
*** Operating free cash flow EUR -23.0m in 2023*

Nanoform - Key Strategy

All API's should be *Starmapped –** a smart, cost/time-efficient, and green way to select medicines candidates for nanoforming.

Nanoform work with customers to enable both *novel & existing molecules* to become new and improved medicines. We provide unique formulated nano-drug-products for small molecules and biological assets.

In parallel, to show a conservative industry the power of nanoforming, we create up to a dozen '*product kernels*'. First, we find development partners and after pilot human studies commercialization partners. The product kernels are within: *oral solids, long acting injectables, inhaled products and biologics.*

Product Kernels

CFO Albert Hæggström

Business case Amorphous Solid Dispersions (ASDs)

Amorphous solid dispersion (ASD) medicines are currently the leading formulation strategy for poorly soluble APIs and there are ~50 marketed medicines globally that are ASDs and sell for ~$50bln annually

Nanoformed and nanocrystalline medicines (e.g. nanoenzalutamide and nanoapalutamide etc) offer an attractive alternative to ASD medicines (and other) with the following benefits:

- ***substantially higher drug load in the final drug product***
- ***reduced pill burden for the patient***
- ***opportunity to extend IP protection for the reformulated and improved product***
- ***opportunity for earlier market entry***

⇨ ***Several opportunities for Nanoform to replicate early successes with project nanoenzalutamide and project nanoapalutamide***

STARMAP® predicts that nanoforming is an attractive alternative to ASD (Amorphous Solid Dispersions)



- ✓ STARMAP predicts that 78% of marketed ASD APIs fall within our processing “sweet spot"
- ✓ 46 ASDs have been Starmapped
- ✓ There are ~50 ASDs on the market selling globally for ~USD 50bn, while there are 30+ candidates disclosed in the clinical pipe-line and most likely hundreds in the preclinical state.
- ✓ The Nanoenzalutamide and Nanoapalutamide projects are first examples of what nanoforming potentially can do to/for ASDs

Nanoform uses its expertise at the interface of nanoparticles and polymer science to enable a more patient- and planet centric alternative to ASDs

Within marketed ASDs 31/39 passed our STARMAP® screen and are predicted to be amenable to nanoforming*

Belsomra®	suvorexant
Braftovi®	encorafenib
Cesamet®	nabilone
Deltyba®	delamanid
Erleada®	apalutamide
Febuxostat®	febuxostat
Gavreto®	pralsetinib
Incivek®	telaprevir
Intelence®	etravirine
Jinarc/Samsca®	tolvaptan
Kaletra®	ritonavir/lopinavir
Kalydeco®	ivacaftor
Lynparza®	olaparib
Norvir®	ritonavir
Noxafil®	posaconazole
Orkambi®	ivacaftor/lumacaftor
Pifeltro®	doravirine
Prezista®	darunavir
Prograf®	tacrolimus
Qinlock®	ripretinib
Sotyktu®	deucravatinib
Sporanox®	itraconazole
Stivarga®	regorafenib
Sunlenca®	lenacapavir
Symdeco/Symkevi®	ivacaftor/tezacaftor
Tavneos®	avacopan
Trikata®	ivacaftor/tezacaftor/elexecaftor
Tukysa®	tucatinib
Xtandi®	enzalutamide
Zokinvy®	lonafarnib
Zortress®	everolimus

From the list of 31 products, we have identified 7 'product kernels' where we see great potential to show the industry the power of nanoforming

Technical, financial and IP analysis of:

31

ASD products

(Amorphous solid dispersed medicines)

Partnering discussions:

- ✓ Commercial terms
- ✓ Fit to strategy/pipeline
- ✓ Timelines

7*

Partner Programs:

- ✓ Partnering deals in 2024-26
- ✓ Product launches 2027=>

*** Includes the announced nanoenzalutamide and nanoapalutamide projects**

All product kernels are planned to be partnered out during 2024-2026 to either the originators or valued add medicine companies, with milestones and royalties

Nanocrystalline alternatives to ASD's under development

Nanoform 'product kernel' project data					Preclinical (Nanoform)				Clinical (Nanoform)		Commercial (Nanoform)		
Project	Originator	API	Indication	Delivery route / dosage form	CESS PoC* + polymer screen	Intermediate drug product + in-vitro	Dosage form development + in vivo	CESS PoP* / Dosage form development	Phase 1 / Pilot	Pivotal	Commercial partnering window	Targeted market launch	Expected originator peak sales*
OnConcept (Development partner)	Astellas/ Pfizer	Nanoenzalutamide	Prostate cancer	Oral/ tablet							2024	2027	>$5bln
NAN024	Johnson & Johnson	Nanoapalutamide	Prostate cancer	Oral/ tablet							2024-25	2032	>$5bln
NAN030	Undisclosed	Undisclosed	Oncology	Oral/ tablet							2025-26		
NAN027	Undisclosed	Undisclosed	Oncology	Oral/ tablet							2025-26		
Undisclosed (Development partner)	Undisclosed	Undisclosed	Inflammation	Oral/ tablet							2025		
NAN032	Undisclosed	Undisclosed	Oncology	Oral/ tablet							2025-26		



nanoform

* PoC = Proof of Concept
* PoP = Proof of Process
* Sources: Pharmacircle and Decision Resources, Inc.

Commercial

CCO Christian Jones

Nanoform has made substantial progress in Nanoforming solutions with in-vitro, in-vivo, and clinical study results

Oncology: **Replaced amorphous solid dispersion (ASD) formulations with nanocrystalline high drug load formulations**, matching bioequivalence for Enzalutamide and Apalutamide where life cycle management **opportunities to reduce tablet burden to a single, smaller, easier-to-swallow tablet** as well as working on Aprepitant in partnership with PlusVitech for lung cancer to develop a regimen with substantially fewer tablets.

Inhalation: **Engineering nanoformulations of both small and large molecules** with excellent fine-particle dose (FPD) and fine-particle fraction (FPF) performance in comparison to spray drying technologies. In biologics, Nanoform has shown FPF >95% vs 50% with spray drying for delivering **high drug load** to the lungs.

Biologics: Demonstrated in partnership, with Takeda and other companies, **ultra-high concentrations for subcutaneous drug delivery** with acceptable viscosity for injection (Takeda – Plasma Derived Therapies).

Ophthalmic: **Multiple projects where nanoparticles have shown improved delivery potential. High drug load** to the eye enabling smaller implants with no requirement for mesh membranes, eye drop suspensions and ophthalmic inserts.

Hydrogels: **Shown high drug load** applications (5 x more than nanomilling) for post-surgical glioblastoma drug delivery and deep penetration across the brain parenchyma **enabling non-recurrence of glioblastoma** where other formulations failed.

IP: **Novel technologies, processes and formulations** can enable market opportunities, lifecycle management and strong launch strategies

Nanoform customer projects – therapy area overview*

Pre-Clinical	Phase I	Phase II & III	Marketed/505b2
Cardiology (e.g. Anemia)	Immunology/Inflammation (e.g. Cystic Fibrosis)	Metabolism and Endocrinology (e.g. Adrenal Hyperplasia)	Infectious Disease (e.g. HIV)
Gastroenterology (e.g. Microbiome)	Dermatology/Oncology (e.g. Basal Cell Carcinoma)	Neurology (e.g. Schizophrenia)	Immunology/Inflammation (e.g. HEP B)
Immunology/Inflammation (e.g. Psoriasis)	Neurology (e.g. Parkinsons)	Oncology (e.g. lung cancer)	Immunology/Inflammation) (e.g. Cystic Fibrosis)
Infectious Disease (e.g. HIV)	Oncology (e.g. Solid Tumors)		Oncology (e.g. Prostate Cancer)
Metabolism and Endocrinology (e.g. Diabetes)	Ophthamology (e.g. Cataract)		Ophthamology (e.g. Glaucoma)
Neurology (e.g. Parkinsons)	Pain (e.g. Post Operative Pain)		
Oncology (e.g. Multiple Myeloma)	Infectious Disease (e.g. HIV)		
Ophthamology (e.g. Glaucoma)			
Respiratory (e.g. COPD)			

Nanoform commercial highlights 2024 YTD

August	**Nanoform initiates collaboration with Takeda on their plasma-derived therapy development (biologics)**
July	**New US major pharma signed multi-API contract**
May	**Nanoformed high-concentration biologics formulation for subcutaneous delivery results presented by Takeda at DDF summit in Berlin**
	Celanese showcases Nanoform's technology for long acting small molecule drug release at DDF summit in Berlin
April	**Global top 5 animal health company signed new multi-API contract**
	Nanoform enters sales partnership with CBC to bring best-in-class nanomedicine technology to Japan
	Nanoform and PlusVitech partner to repurpose aprepitant as a treatment for lung cancer
February	**Nanoapalutamide study demonstrates the advantages of Nanoforming over traditional cancer treatment formulations**
January	**Nanoform announces important milestone with promising clinical results for patient-centric Nanotechnology-enhanced Nanoenzalutamide**

Cumulative number of customers signed



Cumulative number of customer projects signed



13 new customer projects signed so far in 2024

Commercial Relationships 2019 - 2024 YTD

Customer mix

11 major pharma



35 mid-sized, specialty pharma & biotech companies

2 co-developments

3 collaborations

Selection of partners

Takeda

GSK

SANOFI

Boehringer Ingelheim

AstraZeneca

Celanese

Bill & Melinda Gates foundation

Upcoming events

September 16-17	14th American DDF Summit, San Diego
September 19	Pareto Securities' 15th Annual Healthcare Conference, Stockholm
October 8-10	CPHI Milan 2024
October 20-23	AAPS PharmSci 360, Salt Lake City
October 28-29	14th annual Partnership Opportunities in Drug Delivery (PODD), Boston
November 4-6	Bio-Europe Autumn, Stockholm
November 18	Nanoform Interim Report January-September 2024
November 20	SEB's Healthcare Seminar 2024, Stockholm
November 26	DNB's 15th Annual Nordic Healthcare Conference, Oslo
November 26-27	BOS Manchester
December 11-13	DDL 2024, Edinburgh
January 13-16	JPM Healthcare Conference 2025
February 27	Nanoform Financial Report 2024
March 16-20	DCAT NYC

Q & A

Nanoform headquarters in Helsinki, Finland

www.nanoform.com

San Diego - New York - Lisbon - Oxford - London - Cambridge - Bordeaux - Stockholm - Budapest - Helsinki


APPENDIX

Simplified value chain

High level overview of Nanoform's value chain and business model



Clients

- Global large pharma
- Mid-sized and specialty pharma
- Biotech



nanoform
small is powerful®

Revenue

- Fixed fee per project
- Royalty as a % based on drug sales or supply price per kg

**API = Active Pharmaceutical Ingredient*

Nanoform - What & How

Nanoform is the medicine performance-enhancing company that leverages best-in-class innovative:

- *nanoparticle engineering technologies*
- *expert in nanoformulation*
- *scalable GMP nano-API manufacturing to enable superior medicines for patients*

Nanoform reduces clinical attrition and enhances drug molecules' performance through:

- *improved bioavailability and drug delivery profiles*
- *differentiation, for example alternative medicine delivery routes, fewer tablets, greener products etc.*
- *patient convenience/adherence*
- *extending the lifecycle*

Revenue drivers & industry attrition rates

Nanoform pre-clinical and clinical revenue drivers

	Non-GMP	GMP
Proof of Concept (PoC)	➢ # of active customers ➢ # of APIs per customer ➢ Price per PoC per API	
Phase I, II & III and/or 505(b)(2)		➢ Attrition between previous and current phase ➢ Price per phase per API ➢ Time lag between previous and current phase ➢ # of customers with 505(b)(2) strategy ➢ Proportion of new drug candidates and 505(b)(2) APIs
Proof of Process (PoP)	➢ Attrition between PoC and PoP ➢ Price per PoP per API ➢ Time lag between PoC and PoP	
Drugs on the market		➢ # of drugs on the market using CESS® ➢ License fee & royalty level per drug ➢ Net revenues per drug ➢ Time lag Phase II and market (505b2) ➢ Time lag Phase III and market ➢ Speed of uptake on market

Global Pharmaceutical industry's pre-clinical and clinical success rates



Timeline (years)	Pre-clinical	Phase I	Phase II	Phase III	Approval	Total
New drugs	~1-4	~2	~2	~3-4	~1	~9-13
Existing drugs	-	Clinical development for 505(b)(2) ~2-5			~1	~3-6

Source: Company information; Takebe, Imai & Ono (2018), Clinical and Translational Science (11) (Pre-clinical to Phase I); Biotechnology Innovation Organization, Biomedtracker and Amplion, Clinical Development Success Rates 2006-2015 (Clinical success rates); Kaur, Sharma & Sharma (2014), Journal of Drug Delivery and & Therapeutics (4) (Timeline); The Pharmaceutical Journal, Drug Development: The Journey of a Medicine from Lab to Shelf (Timeline); Camargo Pharmaceutical Services, Understanding the 505(b)(2) Approval Pathway (Timeline); 1) Non-NMEs often use 505(b)(2) pathway to gain FDA approval, source: Biotechnology Innovation Organization, Biomedtracker and Amplion 2) Academic drug discovery, NME consisting only of small molecules

Nanoform – Attractive revenue model

Predictable revenue streams through capitalizing the entire pharmaceuticals value chain

Phase	Proof of Concept / Proof of Process	Phase I – III trials	Drugs on the market
Certification	Non-GMP	GMP	GMP
Description	• *Proof of concept study* - assessment of the possibility to nanoform a specific API • *Proof of process study* - definition of parameters to establish the optimal process and controls for a specific API	• API for clinical trials are manufactured in Nanoforms GMP facility • Supply of material for customers' Phase I, II and III trials • Nanoform gets paid regardless of the outcome of the trials	• Drugs that have passed the trials and reached commercialization • In practice, if a company has taken its drug through Phase II trials, it is difficult to switch manufacturer • Significant potential from patent extension (505b2 projects) of drugs already on the market
Revenue model	Fixed fee per project *Estimated project fee of EUR 50-500k per API per project*	Fixed fee per project *Estimated project fee of EUR 0.5-10m per API per phase*	Royalty as a % on drug sales or supply price per kg *Estimated royalty fee of 1-20%*

Nanoform mid-term business targets 2025

>70
new APIs per year

35 lines of which 7-14 are GMP compliant

200-250
employees

>90%
gross margin

Cash flow positive

Nanoform Can Improve the Performance of both Small and Large Molecule Medicines with Two Innovative Processes

Green technology



CESS®	Parameter	BIO Nanoforming
Poorly water soluble	API	Water soluble
Small molecule ≤ 1000 Da	API size	Small or large molecule
Supercritical CO_2	Solvent	Aqueous and/or organic
No excipients involved	Excipients	buffers, sugars, polymers, surfactants
T ≥ 50 °C	Temperature	< 50 °C
Above 300 bar	Pressure	1 bar
Improve oral bioavailability	Typical case	Enable alternative route of administration



Green technology

Controlled Expansion of Supercritical Solutions - CESS®



1. Supercritical CO_2 is guided into a pressure vessel loaded with API
2. Increasing the pressure and temperature in the vessel dissolves the API in supercritical CO_2
3. The CO_2 and the API are released from the pressure vessel and the flow, pressure and temperature profiles are accurately controlled
4. The pressure and temperature is controlled to achieve a stable nucleation phase and formation of nanoparticles
5. In a collection vessel the CO_2 is sublimated resulting in final nanoparticles ready for collection and formulation

➢ **Relatively simple process developed through combining deep knowledge in physics, chemistry, and pharma**

Large molecules - Proprietary technology

Green technology

Nanoforming process for biologics

1. API containing feed solution is pumped into the nebulizer
2. Feed solution is nebulized into a carrier gas
3. Mist is transported into the drying chamber via a connection pipe
4. Mist is dried using low-temperature drying gas
5. Dried particles are charged by the ionizer and collected using electrostatic precipitation



nanoform

API = active pharmaceutical ingredient
Nebulization = turns liquid into mist
Ionization = particles electrically charged

CESS® Superior to Existing Technologies

	Controlled Expansion of Supercritical Solutions (CESS®)	Solid dispersion (e.g. spray drying)	Jet milling	Nanomilling
Description	Extracts API from supercritical CO_2 by applying controlled reduction in pressure	API is dispersed into a solid material, which dissolves when exposed to an aqueous media	Application of energy to physically break down API particles to finer ones	API particle size is reduced in a liquid vehicle via grinding
Particle size	Down to 10nm	300nm-25µm	800nm-10µm	>150nm
Particle formation	Controlled crystalline or amorphous and stable	Amorphous (unstable without excipients)	Unstable (crystalline and amorphous structures)	Unstable (crystalline and amorphous – needs excipient to stabilise)
Ease of formulation	✓	✗	✗	✗
Reproducibility	✓	✓	✗	✗
Free from excipients and solvents	✓	✗	✓	✗
Yield	High	Low	High	Low
Investment	Low	High	Low	Low

Selection of Nanoform Institutional Shareholders

Management team: Multi-disciplinary with international merits

CEO & Co-founder; Ph.D. (Applied physics), MBA

Edward Hæggström

- Professor at the University of Helsinki, Head of Electronics Research Lab. within the Dept. of Physics
- Previously visiting professor at Harvard Medical School, visiting scholar at Stanford University and project leader at CERN
- Has led large number of scientific projects
- *Current ownership: 5,409,405 shares and 204,000 options*

CCO; M.Sc. (Chemistry)

Christian Jones

- Previously Commercial Director and member of the Senior Leadership Team for the Global Health Sector at Johnson Matthey
- Senior roles at Dr. Reddy's Global Custom Pharma Solutions and Prosonix
- **Key area of responsibility:** Commercial strategy and business development
- *Current ownership: 384,000 options*

General Counsel & Chief Development Officer; LL.M

Peter Hänninen

- Previously Attorney, Borenius Attorneys
- Successful track-record of advising technology companies from founding to exit in key transactions and collaborations
- **Key area of Responsibility:** Legal, Compliance, IPR, HR, IT
- *Current ownership: 103,125 shares and 530,000 options*

Chief Quality Officer, M.Sc. (Pharmacology)

Johanna Kause

- Previously Head of Quality, Regulatory and Safety for Finland and the Baltics at Takeda Pharmaceuticals
- 25 years of experience in Quality Management in the Pharma sector
- **Key area of responsibility:** Quality Management, GMP, GDP
- *Current ownership: 130,000 options*

CFO and member of the Board; B.Sc. (Economics)

Albert Hæggström

- 20 years of finance and investing experience
- Prior roles include positions at Alfred Berg, BNP Paribas, Nordea and SEB
- *Current ownership: 711,494 shares and 670,000 options*

Head of Manufacturing; Ph.D. (Chemistry)

David Rowe

- Previously Particle Size Reduction Lead for GlaxoSmithKline
- Chaired the PSR Centre of Excellence
- **Key area of responsibility:** Technical leadership within new chemical entities and commercial assets
- *Current ownership: 413,720 options*

Chief of Business Operations (Chemistry and Quality)

Antonio da Silva

- Degree in Chemistry from Lisbon University and Master degree in Quality from the University Aberta of Lisbon
- Extensive background in the CDMO and particle engineering space (19 years at Hovione)
- **Key area of responsinility:** Pharmaceutical product launches
- *Current ownership: 24,500 shares and 224,516 options*

Board of directors: Top executives from leading industry positions

Miguel Calado

Chairman of the Board

- Previously CFO at international particle engineering CDMO company Hovione Group
- Other previous roles include CFO at PepsiCo International and President International Operations at Dean Foods
- Experienced Board member in both the EU and the US
- *Current ownership: 70,043 shares and 380,000 options*
- **Key experience:**

PEPSICO Hovione Dean FOODS

Albert Hæggström

CFO and Board Member

- 20 years of finance and investing experience
- Prior roles include positions at Alfred Berg, BNP Paribas, Nordea and SEB
- *Current ownership: 711,494 shares and 670,000 options*
- **Key experience:**

Alfred Berg BNP PARIBAS Nordea SEB

Mads Laustsen

Board Member

- Over 30 years of experience in pharmaceutical development and manufacturing
- Co-Founder and former CEO of international biologics CDMO company CMC Biologics and former CEO of Bactolife A/S
- Extensive experience in process development and patenting
- Senior positions within several Danish biotech companies
- *Current ownership: 25,649 shares and 300,000 options*
- **Key experience:**

CMC biologics BACTOLIFE symphogen

Jeanne Thoma

Board Member

- 30+ years of experience in global pharmaceutical and life science leadership
- Prior roles include executive positions at BASF Inc, Lonza AG and SPI Pharmaceuticals
- *Current ownership: 25,649 shares and 38,630 options*
- **Key experience:**

BASF We create chemistry Lonza SPI Pharma An ABF Ingredients Company

Important milestone with very promising clinical results for patient-centric nanotechnology-enhanced Enzalutamide – Jan 26th, 2024

Clinical trial: **Very promising relative bioavailability study of nanocrystalline-enabled enzalutamide (nanoenzalutamide) tablet formulation**

Nanoforming benefits:

- **Opportunity for an improved and differentiated finished product**
- **Development of a 160mg, single tablet per day regimen may be preferable for patients in need of reducing their total number of daily pills**
- **Unique IP position may allow the nanoenzalutamide product to enter the market prior to other generic competition based on the ASD formulation, which is currently patent protected in the US and Europe until 2033**

Next steps: **Manufacture Nanoformed material for registration batches and EU/US pivotal bioequivalence clinical trials that are expected to start in 2024 - with read-outs in 2025, licensing deals targeted to be signed in 2024**

Target launch: **Submissions of dossiers 2025-26, launch after expiry of the enzalutamide substance patent in USA 2027 & in Europe 2028**

***Xtandi® is a registered trademark of Astellas Pharma Inc.**

Comparison of Nanoform's proprietary biologics technology vs existing technologies - A picture tells a thousand words

Nanoform



D50: 0.4 µm

Spray dried



D50: 3.5 µm

Lyophilized



Takeda showcases Nanoform technology for high concentration biologics



Celanese showcases Nanoform technology for long acting small molecule drug release

Project Glioblastoma

Nanoform customer TargTex S.A. was granted Orphan Drug Designation by FDA for its nanoformed drug candidate TTX101 to be used in patients with malignant gliomas

The hydrogel nanoformulation developed by Nanoform enabled a 200-fold increase in drug load compared to bulk and a 5-fold increase in drug load compared to nanomilling

In November 2023, the European Innovation Council and SMEs Executive Agency (EISMEA) awarded TargTex €14m in funding

TargTex is currently raising additional funds to take this innovative treatment to clinic and is planning a phase 1/2a clinical trial in recurrent glioblastoma (GBM) patients across the US and EU, in which nanoformed TTX101 is applied as adjunct to surgery after tumour excision

Find press release here: Nanoformed TargTex oncology drug candidate TTX101 receives FDA Orphan Drug Designation – Nanoform small is powerful

nanoform
small is powerful®

FURTHER ENQUIRIES

CEO Edward Hæggström - edward.haeggstrom@nanoform.com, +358 29 370 0150
CFO Albert Hæggström - albert.haeggstrom@nanoform.com, +358 29 370 0150
DIR Henri von Haartman - hvh@nanoform.com, +46 76866 50 11